CoChat
Sign Up
Cited by 275Clostridium difficile and Clostridium perfringens researchGut microbiota and healthGastrointestinal motility and disorders

The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.

Fecal Microbiota Transplantation: Indications, Methods, Evidence, and Future Directions

Open access
Borody, Thomas J., Paramsothy, Sudarshan, Agrawal, Gaurav·2013·Current Gastroenterology Reports
DOI 10.1007/s11894-013-0337-1PMC PMC3742951
Open this paper in CoChat — free accountOpen PDF

Abstract

Fecal microbiota transplantation (FMT) has attracted great interest in recent years, largely due to the global Clostridium difficile infection (CDI) epidemic and major advances in metagenomic sequencing of the gastrointestinal (GI) microbiota, with growing understanding of its structure and function. FMT is now recommended as the most effective therapy for relapsing CDI and, with further refinement, may even be used in "first-time" CDI. There is interest also in other conditions related to GI dysbiosis--for example, inflammatory bowel disease, irritable bowel syndrome, obesity, and diabetes mellitus--although quality evidence is at present lacking. A few trials are now underway in FMT for ulcerative colitis. Many unanswered questions remain, including FMT methodology--for example, optimal route of administration, what makes a "good donor," safety issues, and long-term effects of FMT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11894-013-0337-1

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 A 33-year-old male with ulcerative colitis presented with abdominal pain, bloody diarrhea, and mucus discharge. Failing standard antiinflammatory drugs with frequent relapses, fecal microbiota transplantation (FMT) was introduced. FMT was first administered via a transcolonoscopic route followed by daily enemas, reducing to twice weekly, weekly, and then fortnightly. After 80 FMT infusions, he was passing normal stool once per day and was off all drugs for 7 months. He was recolonoscoped, and the difference is shown
Fig. 1 A 33-year-old male with ulcerative colitis presented with abdominal pain, bloody diarrhea, and mucus discharge. Failing standard antiinflammatory drugs with frequent relapses, fecal microbiota transplantation (FMT) was introduced. FMT was first administered via a transcolonoscopic route followed by daily enemas, reducing to twice weekly, weekly, and then fortnightly. After 80 FMT infusions, he was passing normal stool once per day and was off all drugs for 7 months. He was recolonoscoped, and the difference is shownCC BY-NC · PubMed Central
Fig. 2 A 14-year-old boy with Clostridium difficile and severe Crohn’s ileitis poorly controlled on prednisone and azathioprine was treated with fecal microbiota transplantation, with a total of 60 home infusions. He experienced marked clinical improvement, and, incidentally, his severe facial acne also healed within 7 days. Ileoscopy showed pronounced improvement in the inflammation, and Clostridium difficile infection cure was confirmed upon stool testing
Fig. 2 A 14-year-old boy with Clostridium difficile and severe Crohn’s ileitis poorly controlled on prednisone and azathioprine was treated with fecal microbiota transplantation, with a total of 60 home infusions. He experienced marked clinical improvement, and, incidentally, his severe facial acne also healed within 7 days. Ileoscopy showed pronounced improvement in the inflammation, and Clostridium difficile infection cure was confirmed upon stool testingCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Research works printed but not linked: 5

  1. Andrews PJ, Barnes P, Borody TJ. Chronic constipation reversed by restoration of the bowel flora.A case and a hypothesis. European J Gastroenterol Hepatol. 1992;4:245–7.
  2. Borody T, Leis S, McGrath K et al. Treatment of Chronic Constipation and Colitis using human probiotic infusions. Probiotics, Prebiotics and New Foods Conference, Universita Urbaniana, Rome, Sept 2–4 2001
  3. Borody TJ, Leis S, Campbell J, et al. Fecal microbiota transplantation (FMT) in multiple sclerosis (MS) [abstract]. Am J Gastroenterol. 2011;106:S352.
  4. Anathaswamy A. Fecal transplant eases symptoms of Parkinson’s. New Scientist Issue. 2011;2796:19.
  5. 58: Kahn SA, Goeppinger SR, Rubin DT. Fecal Transplantation: a new therapy for IBD? Proceeding with Caution. Inflamm Bowel Dis Monit 2013; accepted manuscript [in press]

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Borody, T. J., Paramsothy, S., & Agrawal, G.
Affiliations
  • Centre For Digestive Diseases (AU)
  • St Vincent's Hospital Sydney (AU)
Corresponding author
Borody, Thomas J.
ORCID
Venue
Current Gastroenterology Reports
Publisher
Springer Science and Business Media LLC
Published
2013-07-14
Volume
15
Issue
8
Pages
337-337
ISSN
  • 1522-8037 (ISSN-L)
  • 1534-312X
DOI
10.1007/s11894-013-0337-1
PMC
PMC3742951
OpenAlex
W2112681005
Cited by
275
References
62
Citations by year
2026: 7 · 2025: 11 · 2024: 23 · 2023: 25 · 2022: 15 · 2021: 41 · 2020: 21 · 2019: 20 · 2018: 22 · 2017: 23 · 2016: 20 · 2015: 19 · 2014: 22 · 2013: 6
FWCI
2.90
Type
journal article
Language
en
Open access
Licence
Locations
  • Current Gastroenterology Reports (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
U.S. Food and Drug Administration
Topics
  • Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
fecal microbiota transplantation, Clostridium difficile infection, gut dysbiosis, gut microbiota, inflammatory bowel disease, ulcerative colitis, irritable bowel syndrome, obesity, diabetes mellitus, donor selection, route of administration
MeSH terms
Biological Therapy, Enterocolitis, Pseudomembranous, Feces, Humans, Inflammatory Bowel Diseases, Evidence-Based Medicine, Gastrointestinal Tract, Irritable Bowel Syndrome, Microbiota

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review